Intellia Therapeutics, Inc (NTLA) Stock Price

NTLAStock

$13.51+19.39%52W

Market Cap$1.89B

P/E—

PEG Ratio—

Div yield—

Beta1.79

NTLA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.61%

Price vs S&P 500 (4W)12.28%

VGM Score44.84

Book Value / Share (Quarterly)$5.20

P/TBV (Annual)2.25x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)9.09%

Cash Flow / Share (Quarterly)$-2.49

Price vs S&P 500 (YTD)27.75%

Net Profit Margin (TTM)-672.16%

EPS (TTM)$-3.36

10-Day Avg Trading Volume3.22M

EPS Excl Extra (TTM)$-3.36

Revenue Growth (5Y)3.14%

EPS (Annual)$-3.81

ROI (Annual)-61.47%

Net Profit Margin (5Y Avg)-910.70%

Cash / Share (Quarterly)$3.13

Revenue Growth QoQ (YoY)-46.23%

ROA (Last FY)-49.01%

Revenue Growth TTM (YoY)12.58%

EBITD / Share (TTM)$-3.47

ROE (5Y Avg)-46.19%

Operating Margin (TTM)-711.66%

Cash Flow / Share (Annual)$-3.40

P/B Ratio2.30x

P/B Ratio (Quarterly)3.25x

Net Income / Employee (Annual)$-1,094,700

EV / Revenue (TTM)26.32x

Net Interest Coverage (TTM)-185.69x

ROA (TTM)-47.29%

EPS Incl Extra (Annual)$-3.81

Current Ratio (Annual)5.08x

Quick Ratio (Quarterly)5.61x

3-Month Avg Trading Volume5.88M

52-Week Price Return19.39%

Revenue / Employee (TTM)$157,800

Tangible BV / Share (Quarterly)$11.64

P/S Ratio (Annual)24.71x

Asset Turnover (Annual)0.08x

52-Week High$28.25

Operating Margin (5Y Avg)-936.95%

EPS Excl Extra (Annual)$-3.81

CapEx CAGR (5Y)-20.65%

Tangible BV CAGR (5Y)32.67%

26-Week Price Return0.64%

Quick Ratio (Annual)4.42x

13-Week Price Return1.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.65x

Enterprise Value$1.57B

Revenue / Share Growth (5Y)-9.63%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)-6.23%

Revenue / Employee (Annual)$179,500

Pretax Margin (Annual)-609.85%

Cash / Share (Annual)$3.87

3-Month Return Std Dev84.04%

Net Income / Employee (TTM)$-1,060,900

ROE (Last FY)-61.47%

Net Interest Coverage (Annual)-17.53x

EPS Basic Excl Extra (Annual)$-3.81

P/FCF (TTM)29.66x

Receivables Turnover (TTM)6.37x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.36

Receivables Turnover (Annual)7.53x

ROI (TTM)-57.79%

P/S Ratio (TTM)28.10x

Pretax Margin (5Y Avg)-910.70%

Revenue / Share (Annual)$0.62

Tangible BV / Share (Annual)$14.19

Price vs S&P 500 (52W)1.08%

Year-to-Date Return39.71%

5-Day Price Return8.28%

EPS Normalized (Annual)$-3.81

ROA (5Y Avg)-36.29%

Net Profit Margin (Annual)-609.85%

Month-to-Date Return17.60%

Cash Flow / Share (TTM)$-5.25

EBITD / Share (Annual)$-3.98

Operating Margin (Annual)-651.67%

ROI (5Y Avg)-46.19%

EPS Basic Excl Extra (TTM)$-3.36

P/TBV (Quarterly)2.68x

P/B Ratio (Annual)1.55x

Pretax Margin (TTM)-672.16%

Book Value / Share (Annual)$5.77

Price vs S&P 500 (13W)-1.26%

Beta1.79x

P/FCF (Annual)55.86x

Revenue / Share (TTM)$0.45

ROE (TTM)-57.79%

52-Week Low$7.95

vGradeD

gGradeD

mGradeC

vgmGradeC

NTLA Earnings Surprise History

Q2 25-0.98est. -1.01

Q3 25-0.92est. -0.98

Q4 25-0.83est. -0.96

Q1 26-0.81est. -0.90

Q2 26-0.80est. -0.78

NTLA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.70

3.64

3.67

3.54

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
NTLAIntellia Therapeutics, Inc	D	D	C	$13.51
IDXXIdexx Laboratories Inc	D	B	C	$550.01
LNTHLantheus Holdings, Inc	C	B	B	$100.87
CLDXCelldex Therapeutics, Inc	F	F	B	$41.22
NEOGNeogen Corp	C	C	B	$11.64
QDELQuidelOrtho Corporation Common Stock	C	C	C	$15.05
ACHVAchieve Life Sciences, Inc.	F	F	A	$8.17
TKNOAlpha Teknova, Inc. Common Stock	D	C	A	$7.46
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	F	$7.83
MYGNMyriad Genetics Inc	B	C	D	$3.19
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$4.44
ICCCImmucell Corp	C	B	B	$9.84
QCLSQ/C Technologies, Inc. Common Stock	C	—	F	$2.44
TRIBTrinity Biotech plc	B	D	F	$9.71
CDIOCardio Diagnostics Holdings Inc. Common stock	—	C	B	$1.91
BMRABIOMERICA INC	B	D	D	$1.77
VNRXVolitionRx Limited	B	A	F	$0.38
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	D	$2.91
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	C	$0.01

About Intellia Therapeutics, Inc

Intellia Therapeutics develops CRISPR-based gene therapies to treat genetically defined diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, and sickle cell disease. The company employs both in vivo and ex vivo therapeutic approaches across its pipeline. Strategic partnerships with Regeneron and Novartis provide clinical and commercial validation for its gene-editing platform.